Skip to main content

Table 1 Baseline characteristics of the participants by study arm

From: Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment

ArmDPALp value
Sex = male (%)a93 (55.4)90 (54.2)0.921
Age-months (95% CI)b56.85 (51.34–62.356)59.93 (54.32–65.54)0.439
Haemoglobin levels (95% CI)c10.23 (9.95–10.51)10.45 (10.17–10.73)0.272
Asexual parasite density, geometric mean at enrolment (95% CI) by Microscopyb12,828.74 (12,828.74–18,135.92)16,441.55 (13,859.57–19,504.54)0.564
Pfs25 qRT-PCT gametocyte prevalence at baseline,  % (n/N)a82.4 (127/154)*85.1 (126/148)*0.723
Pfs25 qRT-PCT gametocyte density at baseline, geometric mean (95% CI)c0.94 (0.62–1.42)0.85 (0.61–1.19)0.324
  1. CI confidence interval, IQR interquartile range, DP dihydroartemisinin–piperaquine, AL artemether–lumefantrine
  2. *p-value represents the difference between groups. The difference in gametocyte prevalence was tested using Fisher’s exact test
  3. Data included; aprevalence (n/N), bmean (95% CI) or cmedian (IQR)
  4. *Samples for qRT-PCR analysis at enrolment (DP, n = 154 AL, n = 148 p = 0723.) were selected based on the integrity and availability of samples (slides and DBS) for the different time points of follow-up